To all involved - we have a problem

被引:3
作者
不详
机构
[1] Nature Reviews Clinical Oncology,
关键词
APPROVALS;
D O I
10.1038/s41571-018-0052-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:397 / 397
页数:1
相关论文
共 4 条
[1]   2017 FDA drug approvals: number rebounds but average value slips [J].
Baedeker, Mathias ;
Ringel, Michael ;
Panier, Valery ;
Schulze, Ulrik .
NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (02) :87-87
[2]   Approvals in 2016: questioning the clinical benefit of anticancer therapies [J].
Booth, Christopher M. ;
Del Paggio, Joseph C. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (03) :135-136
[3]   Low-value approvals and high prices might incentivize ineffective drug development [J].
Prasad, Vinay ;
McCabe, Christopher ;
Mailankody, Sham .
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (07) :399-400
[4]   Sustainability and affordability of cancer drugs: a novel pricing model [J].
Uyl-de Groot, Carin A. ;
Lowenberg, Bob .
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (07) :405-406